Clinical Trial

GLP-1 Medicines and Mental Health Changes

Completed
View on ClinicalTrials.gov →
Summary
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.
Trial Details
NCT Number NCT07368855
Lead Sponsor University of California, San Diego
Conditions Obesity, Depression, GLP-1
Enrollment 90 participants
Start Date 2024-05-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-27